Skip to main content
Journal cover image

Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study.

Publication ,  Journal Article
Stroup, TS; Lieberman, JA; McEvoy, JP; Swartz, MS; Davis, SM; Capuano, GA; Rosenheck, RA; Keefe, RSE; Miller, AL; Belz, I; Hsiao, JK ...
Published in: Am J Psychiatry
March 2007

OBJECTIVE: The relative effectiveness of newly started antipsychotic drugs for individuals with schizophrenia may depend on multiple factors, including each patient's previous treatment response and the reason for a new medication trial. This randomized, double-blind study compared olanzapine, quetiapine, and risperidone in patients who had just discontinued the older antipsychotic perphenazine. METHOD: Subjects with schizophrenia (N=114) who had been randomly assigned to and then discontinued perphenazine in phase 1 of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia study were reassigned randomly to double-blinded treatment with olanzapine, 7.5-30.0 mg/day (N=38); quetiapine, 200-800 mg/day (N=38); or risperidone, 1.5-6.0 mg/day (N=38). The primary aim was to determine whether there were differences among these three treatments in effectiveness, as measured by time to treatment discontinuation for any reason. Secondary outcomes included reasons for treatment discontinuation and measures of drug tolerability. RESULTS: The time to treatment discontinuation was longer for patients treated with quetiapine (median, 9.9 months) and olanzapine (7.1 months) than with risperidone (3.6 months). There were no significant differences between treatments on discontinuation due to inefficacy, intolerability, or patient decision. CONCLUSIONS: Among this group of patients with chronic schizophrenia who had just discontinued the older antipsychotic perphenazine, quetiapine and olanzapine were more effective than risperidone, as reflected by longer time to discontinuation for any reason. In the context of other results from the CATIE study, the effectiveness and acceptability of antipsychotic drugs appears to vary considerably according to clinical circumstances.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Am J Psychiatry

DOI

ISSN

0002-953X

Publication Date

March 2007

Volume

164

Issue

3

Start / End Page

415 / 427

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Schizophrenic Psychology
  • Schizophrenia
  • Risperidone
  • Quetiapine Fumarate
  • Psychiatry
  • Psychiatric Status Rating Scales
  • Proportional Hazards Models
  • Perphenazine
  • Patient Dropouts
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Stroup, T. S., Lieberman, J. A., McEvoy, J. P., Swartz, M. S., Davis, S. M., Capuano, G. A., … CATIE Investigators, . (2007). Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study. Am J Psychiatry, 164(3), 415–427. https://doi.org/10.1176/ajp.2007.164.3.415
Stroup, T Scott, Jeffrey A. Lieberman, Joseph P. McEvoy, Marvin S. Swartz, Sonia M. Davis, George A. Capuano, Robert A. Rosenheck, et al. “Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study.Am J Psychiatry 164, no. 3 (March 2007): 415–27. https://doi.org/10.1176/ajp.2007.164.3.415.
Stroup TS, Lieberman JA, McEvoy JP, Swartz MS, Davis SM, Capuano GA, et al. Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study. Am J Psychiatry. 2007 Mar;164(3):415–27.
Stroup, T. Scott, et al. “Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study.Am J Psychiatry, vol. 164, no. 3, Mar. 2007, pp. 415–27. Pubmed, doi:10.1176/ajp.2007.164.3.415.
Stroup TS, Lieberman JA, McEvoy JP, Swartz MS, Davis SM, Capuano GA, Rosenheck RA, Keefe RSE, Miller AL, Belz I, Hsiao JK, CATIE Investigators. Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study. Am J Psychiatry. 2007 Mar;164(3):415–427.
Journal cover image

Published In

Am J Psychiatry

DOI

ISSN

0002-953X

Publication Date

March 2007

Volume

164

Issue

3

Start / End Page

415 / 427

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Schizophrenic Psychology
  • Schizophrenia
  • Risperidone
  • Quetiapine Fumarate
  • Psychiatry
  • Psychiatric Status Rating Scales
  • Proportional Hazards Models
  • Perphenazine
  • Patient Dropouts